# A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate

> **NCT06844383** · PHASE2 · RECRUITING · sponsor: **Prostate Cancer Clinical Trials Consortium** · enrollment: 126 (estimated)

## Conditions studied

- Prostate Cancer (Adenocarcinoma)
- mCRPC (Metastatic Castration-resistant Prostate Cancer)

## Interventions

- **DRUG:** Talazoparib with enzalutamide
- **DRUG:** Talazoparib

## Key facts

- **NCT ID:** NCT06844383
- **Lead sponsor:** Prostate Cancer Clinical Trials Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2029-03
- **Final completion:** 2030-03
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2026-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06844383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06844383, "A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06844383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*